The use of polylactic acid/polyglycolic acid copolymer and gelatin sponge complex containing human recombinant bone morphogenetic protein-2 following condylectomy in rabbits.
OBJECTIVE
To examine the results of a polylactic acid/polyglycolic acid copolymer and gelatin sponge complex (PGS) with or without recombinant human bone morphogenetic protein-2 (rhBMP-2) used to treat condylar defects in rabbits.


METHODS
Adult male Japanese white rabbits (n=60; 3kg; 12-16 weeks old) were divided into three groups of 20 each. All rabbits underwent condylectomy. In the two implanted groups, PGS with or without 5 microg of rhBMP-2 was implanted to the condylar defect without fixation. No material was implanted into the control group. Animals were sacrificed at 2, 4, 8, 12 and 24 weeks postoperatively, and the temporomandibular joints (TMJs) were examined histologically.


RESULTS
Four weeks after implantation, growth of bone and cartilage-like tissue was observed in all rabbits that received PGS implants (with and without rhBMP-2). A cartilage-like layer was derived from the bone marrow at the operated surface. There was no growth of bone tissue in the control rabbits, but they also had a cartilage-like layer directly derived from the operated surface.


CONCLUSIONS
This study demonstrated that PGS with or without rhBMP-2 could induce regeneration of new bone and cartilage-like tissue in the TMJ.
Ueki
Koichiro
K
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kanazawa University, Japan. kueki@med.kanazawa-u.ac.jp
Takazakura
Daisuke
D
Marukawa
Kohei
K
Shimada
Mayumi
M
Nakagawa
Kiyomasa
K
Takatsuka
Shigeyuki
S
Yamamoto
Etsuhide
E
D000818:Animals; D001672:Biocompatible Materials; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects; D002356:Cartilage / Q000187:drug effects / Q000473:pathology; D002358:Cartilage, Articular / Q000473:pathology; D019902:Chondrocytes / Q000473:pathology; D004337:Drug Carriers; D005347:Fibroblasts / Q000473:pathology; D005781:Gelatin Sponge, Absorbable; D006801:Humans; D019344:Lactic Acid; D008297:Male; D008335:Mandibular Condyle / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D010006:Osteoblasts / Q000473:pathology; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011817:Rabbits; D011994:Recombinant Proteins; D018709:Statistics, Nonparametric; D013704:Temporomandibular Joint / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid